138 related articles for article (PubMed ID: 35506061)
1. Variability in Content of Piperacillin and Tazobactam Injection.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35506061
[TBL] [Abstract][Full Text] [Related]
2. Lack of Content Uniformity in MMR Vaccine.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35360461
[TBL] [Abstract][Full Text] [Related]
3. Potential Process Control Issues with Pemetrexed.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35967958
[TBL] [Abstract][Full Text] [Related]
4. Spectrometric Analysis of Process Variations in Remifentanil.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 36187755
[TBL] [Abstract][Full Text] [Related]
5. Spectral Intra-Lot and Inter-Lot Variability in Carfilzomib.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Anwar H; Lodder RA
Contact Context; 2023; 2023():. PubMed ID: 37008539
[TBL] [Abstract][Full Text] [Related]
6. FTNIR Spectrometry of Micafungin Sodium Quality.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35360460
[TBL] [Abstract][Full Text] [Related]
7. Spectrometric Analysis of Dantrolene Sodium.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; McGuire C; Lodder RA
Contact Context; 2023; 2023():. PubMed ID: 37424832
[TBL] [Abstract][Full Text] [Related]
8. Spectrometric Results of Process Variations in Dacarbazine.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35035310
[TBL] [Abstract][Full Text] [Related]
9. Levothyroxine Variations by Process Analytical Technology.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
Contact Context; 2022; 2022():. PubMed ID: 35440917
[TBL] [Abstract][Full Text] [Related]
10. Intra-Lot and Inter-Lot Variability in Cosyntropin.
Almeter PJ; Isaacs JT; Hunter AN; Henderson BS; Lodder RA
Contact Context; 2021; 2021():. PubMed ID: 35035309
[TBL] [Abstract][Full Text] [Related]
11. Intra-Lot and Inter-Lot Variability in Ceftaroline Fosamil.
Almeter PJ; Isaacs JT; Hunter AN; Henderson BS; Lodder RA
Contact Context; 2021; 2021():. PubMed ID: 35360663
[TBL] [Abstract][Full Text] [Related]
12. Quality Variations in Thyrotropin Alfa.
Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Samano-Garcia C; Lodder RA
Contact Context; 2023; 2023():. PubMed ID: 37396298
[TBL] [Abstract][Full Text] [Related]
13. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
14. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
Lister PD
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Bryson HM; Brogden RN
Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977
[TBL] [Abstract][Full Text] [Related]
16. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
Johnson DM; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
Perry CM; Markham A
Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
[TBL] [Abstract][Full Text] [Related]
18. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
[TBL] [Abstract][Full Text] [Related]
20. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
Gin A; Dilay L; Karlowsky JA; Walkty A; Rubinstein E; Zhanel GG
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):365-83. PubMed ID: 17547502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
